Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=24509 There's a NBC Nightly News special tonight on the "common cold".... msnbc.com  ..... and some on the Agouron thread are making noise about it. Should be interesting, and I believe that few know of VPHM's efforts with picornaviruses...... Monday on NBC ‘Nightly News' Why does ...http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=2450938013210scaram(o)uche Am J Transplant. 2012 Sep 4. doi: 10.1111/j.1600-6143.2012.04231.x. [Epub ahead of print] Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial. Winston DJ, Saliba F...http://www.siliconinvestor.com/readmsg.aspx?msgid=2850981010/30/2012 2:59:09 PMRobohogsHey Fred – good job. This was one of my bigger mistakes a few years back. I was two leveraged heading into the downturn and was forced to sell off most of my holdings in te predecessor before the takeover completed. I think I do get a few thousand out of this however. Jonhttp://www.siliconinvestor.com/readmsg.aspx?msgid=281189485/1/2012 9:53:01 PMfred hayeshttp://www.siliconinvestor.com/readmsg.aspx?msgid=281171635/1/2012 9:52:31 AMIRWIN JAMES FRANKELWell my calculations were off. On the CC they say that the target of $600M was met in the Q, triggering a payment of $87.5M that will be paid in the 3Q. ijhttp://www.siliconinvestor.com/readmsg.aspx?msgid=281170815/1/2012 9:19:34 AMIRWIN JAMES FRANKEL>> Cost of sales increased over the three month period in the prior year by $13.2 million primarily due to increased Cinryze volume coupled with lower Vancocin volumes and a royalty payment due on Vancocin sales. Anyone know how big that royalty payment is? Just guessing but it looks like at least $5M just to get...http://www.siliconinvestor.com/readmsg.aspx?msgid=281170175/1/2012 8:22:48 AMIRWIN JAMES FRANKELhttp://www.siliconinvestor.com/readmsg.aspx?msgid=281169385/1/2012 7:17:27 AMIRWIN JAMES FRANKEL ViroPharma Incorporated Reports First Quarter 2012 Financial Results [graphic]Press Release: ViroPharma Incorporated – 44 minutes ago EXTON, Pa., May 1, 2012 /PRNewswire/ --ViroPharma Incorporated ( VPHM) reported today its financial results for the first quarter ended March 31, 2012. Since December 31, 2011, we: ...http://www.siliconinvestor.com/readmsg.aspx?msgid=281169355/1/2012 7:15:12 AMIRWIN JAMES FRANKEL>> Thinking maybe this is it for the VPHM drop and adding some now. That is what makes a market. I am more reserved. Would be interested at 15.http://www.siliconinvestor.com/readmsg.aspx?msgid=280847994/16/2012 1:09:16 PMsjemmerihttp://www.siliconinvestor.com/readmsg.aspx?msgid=280843084/16/2012 10:00:15 AMIRWIN JAMES FRANKELThe study looks good. I would think subQ would be favored over IV by the patient all else being equal. But it may not be equal. Looks like the dose of C1 INH needs to be nearly double to get the same effect subQ. Since the dose is expensive to harvest and process, and presumably much of that would be passed thr...http://www.siliconinvestor.com/readmsg.aspx?msgid=279941173/6/2012 5:42:18 PMIRWIN JAMES FRANKEL ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)- Data Presented at the 2012 Annual Meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) - [graphic]Press Release: ViroPharma Incorporated – 7 hours ag...http://www.siliconinvestor.com/readmsg.aspx?msgid=279941053/6/2012 5:37:46 PMIRWIN JAMES FRANKELCinryze®? (C1 Inhibitor [Human]) Now Available in the UK for Routine Prevention of Hereditary Angioedema (HAE) Attacks MAIDENHEAD, England, February 29, 2012 /PRNewswire/ -- - New treatment shown to prevent and treat rare and life threatening genetic disorder - - Therapeutic option is first and only licensed f...http://www.siliconinvestor.com/readmsg.aspx?msgid=279793492/29/2012 7:43:13 AMfred hayes...until the following quarter. But what's a few months among friends? And with a little luck, they could make it in Q1 (I didn't check on seasonality, maybe that's a longshot). fredhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279788512/28/2012 9:53:49 PMIRWIN JAMES FRANKELWell unless VPHM does significantly more (~$74m) than the $66.7M of Cinryze sales in 1Q2012, they will not hit the $600M trigger for the CVR. ijhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279775472/28/2012 1:01:35 PMIRWIN JAMES FRANKELViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results - Company Delivers Record Full Year Product Revenue of $544 Million and Record Full Year Diluted Earnings Per Share of $1.68 - By: PR Newswire Feb. 28, 2012 07:30 AM EXTON, Pa., Feb. 28, 2012 /PRNewswire/ -- ViroPharma Incorporated (...http://www.siliconinvestor.com/readmsg.aspx?msgid=279766182/28/2012 7:55:59 AMIRWIN JAMES FRANKEL>> are we going to get our CVR pay-out this month? I doubt it. My guess is that they will do the "look" quarterly and thus cross $600M this quarter (ending 3/31) and then make the payout. I would think we will get paid before the end of June. I would not complain if they pay sooner. :-) ijhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279489522/14/2012 5:51:53 PMsjemmeriVPHM keeps climbing (quite the 3 year chart). IJ, are we going to get our CVR pay-out this month? stevehttp://www.siliconinvestor.com/readmsg.aspx?msgid=279482302/14/2012 1:09:06 PMRocky9Increase of sales guidance (or at least new guidance - I thought they were not providing guidance for vanco in the past): finance.yahoo.com  "For the year 2012, ViroPharma expects the following: Worldwide net product sales are expected to be $600 to $660 million Net U.S. Cinryze sales are expected to be $310 to ...http://www.siliconinvestor.com/readmsg.aspx?msgid=278632241/5/2012 5:24:12 PMsjemmeri ViroPharma purchases exclusive option to acquire Meritage Pharma 6:00 PM ET 12/22/11 | Briefing.com Co announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS...http://www.siliconinvestor.com/readmsg.aspx?msgid=2784180312/23/2011 11:08:33 AMIRWIN JAMES FRANKELSorry for the confusion I caused. Fred understood. I was tracking the cumulative $600M in Cinryze sales because of the $0.50 CVR.http://www.siliconinvestor.com/readmsg.aspx?msgid=2773457810/29/2011 5:05:17 PMLance Bredvoldhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2773293710/28/2011 2:29:44 PMidos"IJ must be sleeping in after celebrating the ballgame last nite" That explains :-) a stunning victory for the Cardinals (so I've been told).http://www.siliconinvestor.com/readmsg.aspx?msgid=2773220810/28/2011 10:33:45 AMfred hayesIJ must be sleeping in after celebrating the ballgame last nite. He's referring to the total cumulative sales at which point the contingent rights from the Lev deal kick in. Each share gets another 50 cents at $600 million...http://www.siliconinvestor.com/readmsg.aspx?msgid=2773208410/28/2011 9:52:26 AMidosNo way the launch in Germany have that large an effect and I don't see how sales of Cinryze can do a lot more than $300M in 2012. Perhaps ij meant total revenues (assuming no Vancocin generics).http://www.siliconinvestor.com/readmsg.aspx?msgid=2773192310/28/2011 8:29:01 AMLance BredvoldThat's a surprising conclusion to me. Sales of Cinryze increased from $49.1 mm in Q3-10 to $65mm in Q3-11. Two quarters later you are predicting that sales annualized will be $600mm? $150mm in Q1-12? Will the launch in Germany have that large an effect or is there something else I've missed? Best, Lancehttp://www.siliconinvestor.com/readmsg.aspx?msgid=2773168010/28/2011 12:26:22 AMIRWIN JAMES FRANKELhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2773017910/27/2011 1:44:29 PMIRWIN JAMES FRANKEL ViroPharma Incorporated Reports Third Quarter 2011 Financial Results- Quarter Highlighted by Record Net Product Sales, European Launch of Cinryze® (C1 esterase inhibitor [human]) and European Approval of Buccolam® (midazolam, oromucosal solution) - [graphic] tweetEmailPrint Companies: Intellect Neurosciences, In...http://www.siliconinvestor.com/readmsg.aspx?msgid=2773017410/27/2011 1:43:33 PMscaram(o)uchetell me that you care....... Antiviral Res. 2011 Sep 1. [Epub ahead of print] Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Hakki M, Drummond C, Houser B, Marousek G, Chou S. Source Division of Infectious Diseases, Oregon Health & Scienc...http://www.siliconinvestor.com/readmsg.aspx?msgid=276351339/13/2011 5:03:59 PMrkrwHospital Acquired Infections Costly, Preventable By Emily P. Walker, Washington Correspondent, MedPage Today Published: August 24, 2011 [graphic] A program to reduce hospital-acquired infections can save an average of $1.1 million a year, according to results of a new study. In 2002, one in every 20 hospitalized pat...http://www.siliconinvestor.com/readmsg.aspx?msgid=275947258/25/2011 2:47:13 PM